Newsroom

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 12, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 15th Annual BIO Investor Forum on Wednesday, October 19, 2016 at 11:30 AM Pacific Time. The conference is being held at the Westin St. Francis Hotel in San Francisco. A live webcast can be accessed by visiting the investors section of the

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 30, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that a settlement hearing will be held on December 19, 2016 at 3:00 p.m., before the Honorable Denise J. Casper, United States Courthouse, Courtroom No. 11 of the John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, Massachusetts 02210 in the matter of Karen J. van Ingen v. AVEO Pharmaceuticals, Inc., et al., Civil Action No. 1:14-cv-11672-DJC

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 6, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 18th Annual Rodman & Renshaw Global Investment Conference on Monday, September 12, 2016 at 12:30 PM Eastern Time. The conference is being held at the New York Palace Hotel. A live webcast can be accessed by visiting the investors section of

Download PDF –Phase 1/2 TiNivo Trial to Commence at the Institut Gustave Roussy in Paris- CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today announced the initiation of a clinical evaluation of AVEO’s oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), tivozanib, in combination with Bristol-Myers Squibb’s anti-PD-1 therapy, Opdivo® (nivolumab), in advanced renal cell

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 4, 2016– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the second quarter ended June 30, 2016. “The second quarter of 2016 marked a defining moment for AVEO, with the initiation of TIVO-3, our Phase 3 pivotal study of tivozanib in refractory advanced renal cell cancer, and the closing of debt and equity financings to

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 15, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016 at 11:00 AM Eastern Time. The conference is being held at the St. Regis Hotel in New York. A live webcast can be accessed by visiting the investors section of the Company’s

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 26, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that the first patient has been dosed in the Company’s pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor

Download PDF Private Placement Provides Gross Proceeds of Approximately $17 Million;Amended Term Loan to Provide up to $10 Million in Funding CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 18, 2016– AVEO Oncology (NASDAQ:AVEO) today announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock,